Linked Life Data

20925938

Source:http://linkedlifedata.com/resource/pubmed/id/20925938

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20925938rdf:typepubmed:Citationlld:pubmed
pubmed-article:20925938lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:20925938lifeskim:mentionsumls-concept:C0011849lld:lifeskim
pubmed-article:20925938lifeskim:mentionsumls-concept:C0022671lld:lifeskim
pubmed-article:20925938lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:20925938lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:20925938lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:20925938lifeskim:mentionsumls-concept:C0023981lld:lifeskim
pubmed-article:20925938lifeskim:mentionsumls-concept:C1570906lld:lifeskim
pubmed-article:20925938pubmed:dateCreated2010-11-12lld:pubmed
pubmed-article:20925938pubmed:databankReferencehttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20925938pubmed:abstractTextNew-onset diabetes mellitus after transplantation (NODAT), a frequent and serious complication after transplantation, is associated with decreased graft and patient survival. Currently, it is diagnosed and treated primarily according to existing guidelines for type II diabetes. To date, only a few trials have studied antidiabetic drugs in patients with NODAT. Vildagliptin is a novel dipeptidyl peptidase-4 (DPP-4) inhibitor that improves pancreatic islet function by enhancing both ?- and ?-cell responsiveness to increased blood glucose. Experimental data show potential protective effects of DPP-4 inhibitors on islet function after exogenous stress stimuli including immunosuppressants. Therefore, the therapy of NODAT with this class of compounds seems attractive. At present, vildagliptin is used to treat type II diabetes as monotherapy or in combination with other antidiabetic drugs, since that it efficiently decreases glycated hemoglobin (HbA1c) values. Additionally, vildagliptin has been shown to be safe in patients with moderately impaired kidney function. This study will evaluate the safety and efficacy of vildagliptin monotherapy in renal transplant recipients with recently diagnosed NODAT.lld:pubmed
pubmed-article:20925938pubmed:languageenglld:pubmed
pubmed-article:20925938pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20925938pubmed:citationSubsetIMlld:pubmed
pubmed-article:20925938pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20925938pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20925938pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20925938pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20925938pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20925938pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20925938pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20925938pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20925938pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20925938pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20925938pubmed:statusMEDLINElld:pubmed
pubmed-article:20925938pubmed:issn1745-6215lld:pubmed
pubmed-article:20925938pubmed:authorpubmed-author:PleinerJohann...lld:pubmed
pubmed-article:20925938pubmed:authorpubmed-author:HörlWalter...lld:pubmed
pubmed-article:20925938pubmed:authorpubmed-author:SäemannMarcus...lld:pubmed
pubmed-article:20925938pubmed:authorpubmed-author:HaidingerMich...lld:pubmed
pubmed-article:20925938pubmed:authorpubmed-author:WerzowaJohann...lld:pubmed
pubmed-article:20925938pubmed:authorpubmed-author:WeichhartThom...lld:pubmed
pubmed-article:20925938pubmed:authorpubmed-author:HeckingManfre...lld:pubmed
pubmed-article:20925938pubmed:authorpubmed-author:StemerGunarGlld:pubmed
pubmed-article:20925938pubmed:authorpubmed-author:VoigtHans-Chr...lld:pubmed
pubmed-article:20925938pubmed:authorpubmed-author:DöllerDominik...lld:pubmed
pubmed-article:20925938pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20925938pubmed:volume11lld:pubmed
pubmed-article:20925938pubmed:ownerNLMlld:pubmed
pubmed-article:20925938pubmed:authorsCompleteYlld:pubmed
pubmed-article:20925938pubmed:pagination91lld:pubmed
pubmed-article:20925938pubmed:meshHeadingpubmed-meshheading:20925938...lld:pubmed
pubmed-article:20925938pubmed:meshHeadingpubmed-meshheading:20925938...lld:pubmed
pubmed-article:20925938pubmed:meshHeadingpubmed-meshheading:20925938...lld:pubmed
pubmed-article:20925938pubmed:meshHeadingpubmed-meshheading:20925938...lld:pubmed
pubmed-article:20925938pubmed:meshHeadingpubmed-meshheading:20925938...lld:pubmed
pubmed-article:20925938pubmed:meshHeadingpubmed-meshheading:20925938...lld:pubmed
pubmed-article:20925938pubmed:meshHeadingpubmed-meshheading:20925938...lld:pubmed
pubmed-article:20925938pubmed:meshHeadingpubmed-meshheading:20925938...lld:pubmed
pubmed-article:20925938pubmed:meshHeadingpubmed-meshheading:20925938...lld:pubmed
pubmed-article:20925938pubmed:meshHeadingpubmed-meshheading:20925938...lld:pubmed
pubmed-article:20925938pubmed:meshHeadingpubmed-meshheading:20925938...lld:pubmed
pubmed-article:20925938pubmed:meshHeadingpubmed-meshheading:20925938...lld:pubmed
pubmed-article:20925938pubmed:meshHeadingpubmed-meshheading:20925938...lld:pubmed
pubmed-article:20925938pubmed:meshHeadingpubmed-meshheading:20925938...lld:pubmed
pubmed-article:20925938pubmed:meshHeadingpubmed-meshheading:20925938...lld:pubmed
pubmed-article:20925938pubmed:meshHeadingpubmed-meshheading:20925938...lld:pubmed
pubmed-article:20925938pubmed:meshHeadingpubmed-meshheading:20925938...lld:pubmed
pubmed-article:20925938pubmed:meshHeadingpubmed-meshheading:20925938...lld:pubmed
pubmed-article:20925938pubmed:meshHeadingpubmed-meshheading:20925938...lld:pubmed
pubmed-article:20925938pubmed:meshHeadingpubmed-meshheading:20925938...lld:pubmed
pubmed-article:20925938pubmed:meshHeadingpubmed-meshheading:20925938...lld:pubmed
pubmed-article:20925938pubmed:year2010lld:pubmed
pubmed-article:20925938pubmed:articleTitleA randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation.lld:pubmed
pubmed-article:20925938pubmed:affiliationClinical Division of Nephrology and Dialysis, Department of Internal Medicine III, Medical University of Vienna, Austria.lld:pubmed
pubmed-article:20925938pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20925938pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:20925938pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:20925938lld:pubmed